The RTOG Statistics Department was established to collaborate with RTOG investigators in defining the optimum management of cancer patients, particularly when this care includes radiation therapy, either alone or in combination with other modalities. These efforts should lead to extended survival, improved tumor control, enhanced quality of life, and an ultimate cure. To achieve this objective, the Statistical Unit collaborates with RTOG investigators in conducting multicenter randomized and nonrandomized clinical trials to evaluate the safety and efficacy of novel therapies, in the treatment of patients with cancer. The RTOG statisticians work with the RTOG investigators to develop and implement research strategies in a series of well-designed trials. They assure that the role of each new treatment regimen receives adequate phase I/II evaluation. The results can then be incorporated into designing subsequent phase III trials with minimal delay, a minimum but sufficient number of patients, and a maximum chance of detecting clinically significant differences. The RTOG statisticians further collaborate with RTOG investigators in carefully monitoring ongoing trials, performing timely and appropriate analyses, and promptly reporting the results. The RTOG Statistics Department determines randomization schemes and develops systems for processing and analyzing the clinical databases. RTOG also conducts studies in correlating laboratory findings and outcomes research [Quality of Life (QOL), Special Populations (SP), Economic Impact (EI), and Epidemiology Subcommittees (EP)] endpoints with treatment outcome. The laboratory studies may lead to a better understanding of the fundamental nature of the malignant process and predict the responsiveness of tumors to various therapies. The RTOG evaluates every study for potential inclusion of outcome research endpoints. In studies where these endpoints are appropriate, the Statistics Department collaborates with the RTOG investigator on the design of case report forms to obtain the necessary data. Given these findings from the laboratory and the outcomes studies, treatments can be more logically planned for individual patients. The RTOG Statistics Department collaborates with RTOG investigators in the design, monitoring, and analysis of all these studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
American College of Radiology
United States
Zip Code
Li, Donghui; Moughan, Jennifer; Crane, Christopher et al. (2016) RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys 94:554-60
Hamstra, Daniel A; Bae, Kyounghwa; Hanks, Gerald et al. (2015) Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer 121:844-52
Ben-Josef, Edgar; George, Asha; Regine, William F et al. (2015) Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas. Clin Cancer Res 21:5612-8
Hsu, I-Chow; Hunt, Daniel; Straube, William et al. (2014) Dosimetric analysis of radiation therapy oncology group 0321: the importance of urethral dose. Pract Radiat Oncol 4:27-34
Xiao, Canhua; Hanlon, Alexandra; Zhang, Qiang et al. (2014) Risk factors for clinician-reported symptom clusters in patients with advanced head and neck cancer in a phase 3 randomized clinical trial: RTOG 0129. Cancer 120:848-54
Cairncross, J Gregory; Wang, Meihua; Jenkins, Robert B et al. (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783-90
Komaki, Ritsuko; Paulus, Rebecca; Blumenschein Jr, George R et al. (2014) EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol 112:30-6
Xiao, Canhua; Hanlon, Alexandra; Zhang, Qiang et al. (2013) Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. Oral Oncol 49:360-6
Cairncross, Gregory; Wang, Meihua; Shaw, Edward et al. (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337-43
Lawrence, Yaacov Richard; Paulus, Rebecca; Langer, Corey et al. (2013) The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. Lung Cancer 80:298-305

Showing the most recent 10 out of 274 publications